Bank of America Securities analyst Kevin Fischbeck reiterated a Sell rating on Clover Health Investments (CLOV – Research Report) yesterday and set a price target of $1.30. The company’s shares closed yesterday at $0.92.
According to TipRanks, Fischbeck is a 3-star analyst with an average return of 2.7% and a 58.57% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Humana, UnitedHealth, and Universal Health.
Clover Health Investments has an analyst consensus of Hold, with a price target consensus of $1.68.
See Insiders’ Hot Stocks on TipRanks >>
CLOV market cap is currently $454.3M and has a P/E ratio of -1.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clover Health Investments Corp is a healthcare technology company. It uses its proprietary technology platform to collect, structure, and analyze health and behavioral data to improve medical outcomes and lower costs for patients.
Read More on CLOV:
- Clover Health Reports First Quarter 2023 Financial Results
- Clover Health Announces Agreement to Settle Securities Class Action Litigation
- Clover Health enters agreement to settle securities class action litigation
- Clover Health transformation to reduce time to profitability, says Canaccord
- Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability
